Lindsay R. Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lindsay R. Clark has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Nathaniel A. Chin
University of Wisconsin‐Madison School of Medicine and Public Health, Madison, WI, USA
10 shared publicationsClaire M. Erickson
Banner Alzheimer’s Institute, Phoenix, Arizona
8 shared publicationsSterling C. Johnson
University of Wisconsin School of Medicine and Public Health, Madison, WI USA
7 shared publications- Sterling C. Johnson
Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, Madison, USA
7 shared publications Cynthia M. Carlsson
Department of Medicine, Division of Geriatrics University of Wisconsin‐Madison School of Medicine & Public Health Madison Wisconsin USA
6 shared publicationsSanjay Asthana
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
6 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S4) , e105168
Satisfaction and utility in learning research amyloid PET results across the clinical spectrum
Background: Communicating Alzheimer's disease (AD) biomarker results with adults enrolled in observational cohorts is of interest to participants and researchers. The objective of this project is to evaluate participant experience and satisfaction with learning amyloid PET results. Method: Amyloid PET results were provided to 169 late middle‐aged and older adults enrolled in observational cohorts (mean age=69 [SD=7.9]; 63% women; 19% from under‐represented groups [URGs]; 31% cognitively impaired [CI]) (Table 1). Optional surveys assessing clinical and personal utility, result comprehension, clinician competence, and satisfaction were completed approximately 4‐6 months after result disclosure. Summary statistics were computed for each survey item. T‐tests or Mann‐Whitney U tests were conducted to compare responses by amyloid result (elevated, non‐elevated) and cognitive status (unimpaired, impaired). Result: Seventy‐six participants completed surveys (mean age=69 [SD=7.6]; 74% women; 13% URG; 17% CI). Men or those with CI were less likely to complete surveys. Of survey respondents, 92‐100% endorsed items regarding usefulness of educational materials and clinician competence, and 93% understood the meaning of their PET result. Participants endorsed greater willingness to complete the PET scan because they could learn the result (59%) and most felt it was the right decision (95%), useful (82%), and shared results with others (87%). Respondents endorsed lifestyle behavior change (57%), advanced planning (24%), or making an appointment with a healthcare provider (24%) after learning results, and 41% endorsed interest in enrolling in AD clinical trials. Participants with CI, compared to unimpaired adults, were less likely to understand educational materials ( p = .01) and the meaning of their PET result ( p = .05) and more likely to make a healthcare appointment ( p = .001) or changes to advanced planning ( p = .01). CI participants, as well as participants with elevated PET results, were more interested in AD clinical trials ( p < .01). Conclusion: Adults with and without CI were satisfied and found learning AD research biomarker results useful. Improvements to materials or processes are needed to ensure comprehension of results for individuals with CI. Barriers to survey completion by gender or cognitive status need to be identified and addressed to ensure representative feedback. More research is needed to assess actual post‐disclosure behavioral changes and barriers.
- 26 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S4) , e105168
Open AccessSatisfaction and utility in learning research amyloid PET results across the clinical spectrum
Background: Communicating Alzheimer's disease (AD) biomarker results with adults enrolled in observational cohorts is of interest to participants and researchers. The objective of this project is to evaluate participant experience and satisfaction with learning amyloid PET results. Method: Amyloid PET results were provided to 169 late middle‐aged and older adults enrolled in observational cohorts (mean age=69 [SD=7.9]; 63% women; 19% from under‐represented groups [URGs]; 31% cognitively impaired [CI]) (Table 1). Optional surveys assessing clinical and personal utility, result comprehension, clinician competence, and satisfaction were completed approximately 4‐6 months after result disclosure. Summary statistics were computed for each survey item. T‐tests or Mann‐Whitney U tests were conducted to compare responses by amyloid result (elevated, non‐elevated) and cognitive status (unimpaired, impaired). Result: Seventy‐six participants completed surveys (mean age=69 [SD=7.6]; 74% women; 13% URG; 17% CI). Men or those with CI were less likely to complete surveys. Of survey respondents, 92‐100% endorsed items regarding usefulness of educational materials and clinician competence, and 93% understood the meaning of their PET result. Participants endorsed greater willingness to complete the PET scan because they could learn the result (59%) and most felt it was the right decision (95%), useful (82%), and shared results with others (87%). Respondents endorsed lifestyle behavior change (57%), advanced planning (24%), or making an appointment with a healthcare provider (24%) after learning results, and 41% endorsed interest in enrolling in AD clinical trials. Participants with CI, compared to unimpaired adults, were less likely to understand educational materials ( p = .01) and the meaning of their PET result ( p = .05) and more likely to make a healthcare appointment ( p = .001) or changes to advanced planning ( p = .01). CI participants, as well as participants with elevated PET results, were more interested in AD clinical trials ( p < .01). Conclusion: Adults with and without CI were satisfied and found learning AD research biomarker results useful. Improvements to materials or processes are needed to ensure comprehension of results for individuals with CI. Barriers to survey completion by gender or cognitive status need to be identified and addressed to ensure representative feedback. More research is needed to assess actual post‐disclosure behavioral changes and barriers.
- Open Access
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2545774
Health Behavior of Adults Without Cognitive Impairment After Receiving Amyloid-β PET Results
This cohort study explores self-reported health behavior changes of adults without cognitive impairment after receiving amyloid-β positron emission tomography (PET) results.
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2545774
Open AccessHealth Behavior of Adults Without Cognitive Impairment After Receiving Amyloid-β PET Results
This cohort study explores self-reported health behavior changes of adults without cognitive impairment after receiving amyloid-β positron emission tomography (PET) results.
- Open Access
Sex-Specific Differential DNA Methylation in Mild Cognitive Impairment and Alzheimer’s Disease
Sex differences in late-onset Alzheimer’s disease (AD) progression include accelerated decrements in cognitive status and greater amyloid and tau biomarker burdens in females. To identify sex-specific differentially methylated positions (DMPs) and genes in persons with mild cognitive impairment (MCI) and AD, we analyzed whole genome methylation sequencing on blood samples from participants with MCI (N=99, 52% female), AD (N=109, 43% female), and those cognitively unimpaired (CU; N=174, 52% female). Ninety-four percent of DMPs from MCI vs . CU, AD vs . CU, and AD vs . MCI pairwise comparisons were sex-specific. Female-specific DMPs were enriched in neurologic gene sets ( e.g ., synaptic membrane, ion channel complex), while male-specific DMPs showed limited enrichment. Sex-specific DMPs overlapped blood-specific enhancers, promoters, and transcription factor binding motifs, highlighting divergent epigenetic regulation by sex. These findings identify sex-specific genes and molecular pathways in MCI and AD and support that blood DNA methylation levels can distinguish cognitive status.
Open AccessSex-Specific Differential DNA Methylation in Mild Cognitive Impairment and Alzheimer’s Disease
Sex differences in late-onset Alzheimer’s disease (AD) progression include accelerated decrements in cognitive status and greater amyloid and tau biomarker burdens in females. To identify sex-specific differentially methylated positions (DMPs) and genes in persons with mild cognitive impairment (MCI) and AD, we analyzed whole genome methylation sequencing on blood samples from participants with MCI (N=99, 52% female), AD (N=109, 43% female), and those cognitively unimpaired (CU; N=174, 52% female). Ninety-four percent of DMPs from MCI vs . CU, AD vs . CU, and AD vs . MCI pairwise comparisons were sex-specific. Female-specific DMPs were enriched in neurologic gene sets ( e.g ., synaptic membrane, ion channel complex), while male-specific DMPs showed limited enrichment. Sex-specific DMPs overlapped blood-specific enhancers, promoters, and transcription factor binding motifs, highlighting divergent epigenetic regulation by sex. These findings identify sex-specific genes and molecular pathways in MCI and AD and support that blood DNA methylation levels can distinguish cognitive status.
- Open Access
- 6 December 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (4) , 1227-1236
Memory screening in the community: Facilitating earlier dementia diagnosis and care—Preliminary data
Background: This program evaluation was conducted to assess the effectiveness of a community memory screening initiative across 25 Aging and Disability Resource Centers, spanning 39 counties and 5 tribal communities in the state of Wisconsin. Methods: We evaluated the screened individuals' characteristics and reasons for screening, the screen results and topics addressed during screening, the rate of sending positive screens to primary care providers, and the incidence of subsequent dementia diagnosis as well as health behavior changes. Results: Program evaluation results showed 791 completed surveys from individuals, indicating the program's accessibility and potential to reach populations in both urban and rural counties across Wisconsin. Evaluation results also showed that brain health was the most frequently discussed topic during memory screens (discussed during 689 screens, 87.1%), along with other topics such as potential causes of dementia symptoms (670 screens, 84.5%), dementia warning signs (656, 83%), the importance of early detection (605 screens, 76.5%), and caregiver support (106 screens, 13.4%). Of all 791, a total of 273 (34.5%) individuals had screen results sent to a primary care provider. Follow‐up surveys completed with a subset of individuals ( n = 49) who had their results sent to a primary care provider indicated that 10 (20%) received a diagnosis of dementia and over half made a health behavior change to improve brain health. Conclusions: The evaluation results presented herein highlight the program's success in addressing the critical need for accessible dementia‐related services. Overall, our evaluation results underscore the importance of community‐based initiatives in promoting early dementia detection and intervention, which are crucial for disease management.
- 6 December 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (4) , 1227-1236
Open AccessMemory screening in the community: Facilitating earlier dementia diagnosis and care—Preliminary data
Background: This program evaluation was conducted to assess the effectiveness of a community memory screening initiative across 25 Aging and Disability Resource Centers, spanning 39 counties and 5 tribal communities in the state of Wisconsin. Methods: We evaluated the screened individuals' characteristics and reasons for screening, the screen results and topics addressed during screening, the rate of sending positive screens to primary care providers, and the incidence of subsequent dementia diagnosis as well as health behavior changes. Results: Program evaluation results showed 791 completed surveys from individuals, indicating the program's accessibility and potential to reach populations in both urban and rural counties across Wisconsin. Evaluation results also showed that brain health was the most frequently discussed topic during memory screens (discussed during 689 screens, 87.1%), along with other topics such as potential causes of dementia symptoms (670 screens, 84.5%), dementia warning signs (656, 83%), the importance of early detection (605 screens, 76.5%), and caregiver support (106 screens, 13.4%). Of all 791, a total of 273 (34.5%) individuals had screen results sent to a primary care provider. Follow‐up surveys completed with a subset of individuals ( n = 49) who had their results sent to a primary care provider indicated that 10 (20%) received a diagnosis of dementia and over half made a health behavior change to improve brain health. Conclusions: The evaluation results presented herein highlight the program's success in addressing the critical need for accessible dementia‐related services. Overall, our evaluation results underscore the importance of community‐based initiatives in promoting early dementia detection and intervention, which are crucial for disease management.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S3) , e089786
Remote digital memory assessment in middle‐aged and older adults: Feasibility, reliability, and construct validity
Background: Frequent and remote cognitive assessment may improve sensitivity to subtle cognitive decline associated with preclinical Alzheimer’s disease (AD). Our objective was to evaluate the feasibility, reliability, and construct validity of repeated remote memory assessment in late middle‐aged and older adults.Method: Participants were recruited from longitudinal aging cohorts to complete medial temporal lobe‐based memory paradigms (Object‐In‐Room Recall [ORR], Mnemonic Discrimination for Objects and Scenes [MDT‐OS], Complex Scene Recognition [CSR]) using the neotiv application on a smartphone or tablet at repeated intervals over one year. Participants were randomized to a task schedule (biweekly or bimonthly burst) for a total of 24 ten‐minute remote sessions. Feasibility metrics included participation, retention, compliance, and acceptability. Intraclass correlation coefficients (ICC) assessed test‐retest reliability over an 8‐week period. Analysis of covariance (ANCOVA) models including covariates of demographics, device type, and task schedule were used to evaluate relationships between neotiv baseline performance and traditional memory scores (Rey Auditory Verbal Learning Test [RAVLT]; Preclinical Alzheimer’s Cognitive Composite [PACC]).Result: Of 280 potentially eligible adults, n = 180 consented (64% participation rate). Of 180 consented, n = 133 completed at least one session and n = 119 completed or nearly completed all sessions (retention rate = 66% for all consented and 89% for all completed 1+ session). Delayed retrieval sessions were completed within expected timeframes in 72% of sessions. Greater than 90% of respondents felt the application was easy to use, instructions were understood, and the frequency and length of remote sessions were appropriate. 60% enjoyed completing the tasks (34% felt neutral) and 40% preferred mobile tests to traditional cognitive testing (42% felt neutral). Test‐retest reliability was moderate (ICC = 0.54‐0.70). RAVLT and PACC were significantly associated with MDT‐OS, CSR, and ORR performance (p’s <.001).Conclusion: Challenges to participation occurred primarily during enrollment; future studies may allocate additional support facilitating registration and initial task completion within the application. Acceptability of the mobile tasks was high. The mobile memory paradigms exhibited moderate test‐retest reliability and were significantly related to gold‐standard cognitive tests. Overall, findings support preliminary feasibility, reliability, and validity of the neotiv tasks in assessing memory function in cognitively healthy adults enriched for AD risk.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S3) , e089786
Open AccessRemote digital memory assessment in middle‐aged and older adults: Feasibility, reliability, and construct validity
Background: Frequent and remote cognitive assessment may improve sensitivity to subtle cognitive decline associated with preclinical Alzheimer’s disease (AD). Our objective was to evaluate the feasibility, reliability, and construct validity of repeated remote memory assessment in late middle‐aged and older adults.Method: Participants were recruited from longitudinal aging cohorts to complete medial temporal lobe‐based memory paradigms (Object‐In‐Room Recall [ORR], Mnemonic Discrimination for Objects and Scenes [MDT‐OS], Complex Scene Recognition [CSR]) using the neotiv application on a smartphone or tablet at repeated intervals over one year. Participants were randomized to a task schedule (biweekly or bimonthly burst) for a total of 24 ten‐minute remote sessions. Feasibility metrics included participation, retention, compliance, and acceptability. Intraclass correlation coefficients (ICC) assessed test‐retest reliability over an 8‐week period. Analysis of covariance (ANCOVA) models including covariates of demographics, device type, and task schedule were used to evaluate relationships between neotiv baseline performance and traditional memory scores (Rey Auditory Verbal Learning Test [RAVLT]; Preclinical Alzheimer’s Cognitive Composite [PACC]).Result: Of 280 potentially eligible adults, n = 180 consented (64% participation rate). Of 180 consented, n = 133 completed at least one session and n = 119 completed or nearly completed all sessions (retention rate = 66% for all consented and 89% for all completed 1+ session). Delayed retrieval sessions were completed within expected timeframes in 72% of sessions. Greater than 90% of respondents felt the application was easy to use, instructions were understood, and the frequency and length of remote sessions were appropriate. 60% enjoyed completing the tasks (34% felt neutral) and 40% preferred mobile tests to traditional cognitive testing (42% felt neutral). Test‐retest reliability was moderate (ICC = 0.54‐0.70). RAVLT and PACC were significantly associated with MDT‐OS, CSR, and ORR performance (p’s <.001).Conclusion: Challenges to participation occurred primarily during enrollment; future studies may allocate additional support facilitating registration and initial task completion within the application. Acceptability of the mobile tasks was high. The mobile memory paradigms exhibited moderate test‐retest reliability and were significantly related to gold‐standard cognitive tests. Overall, findings support preliminary feasibility, reliability, and validity of the neotiv tasks in assessing memory function in cognitively healthy adults enriched for AD risk.
- Open Access
Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer’s disease identifies cognitive status
INTRODUCTION Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late-onset dementia due to Alzheimer’s disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU). RESULTS WGMS identified 9,756 differentially methylated positions (DMPs) in persons with MCI, including 1,743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport. 447 DMPs exhibit progressively increasing or decreasing DNA methylation levels between CU, MCI, and AD that correspond to cognitive status. DISCUSSION WGMS identifies DMPs in known and newly detected genes in blood from persons with MCI and AD that support blood DNA methylation levels as candidate biomarkers of cognitive status.
Open AccessWhole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer’s disease identifies cognitive status
INTRODUCTION Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late-onset dementia due to Alzheimer’s disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU). RESULTS WGMS identified 9,756 differentially methylated positions (DMPs) in persons with MCI, including 1,743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport. 447 DMPs exhibit progressively increasing or decreasing DNA methylation levels between CU, MCI, and AD that correspond to cognitive status. DISCUSSION WGMS identifies DMPs in known and newly detected genes in blood from persons with MCI and AD that support blood DNA methylation levels as candidate biomarkers of cognitive status.
- Open Access
- 11 August 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (9) , 6579-6589
Psychosocial implications of learning amyloid PET results in an observational cohort
INTRODUCTION: Information on the psychosocial impact of Alzheimer's disease (AD) biomarker testing in adults at risk of AD is needed to inform best practices for communicating biomarker results.METHODS: Ninety‐nine cognitively unimpaired older adults learned amyloid positron emission tomography (PET) results (mean age = 72.0 ± 4.8, 95% White, 28% elevated amyloid). Linear mixed‐effects regression models were used to test the main effects and interaction of PET result × time on psychosocial outcomes up to 6 months after learning results.RESULTS: A significant interaction of PET result × time was observed for concern about AD (β = 0.28, p = 0.02) and intrusive thoughts and avoidance (β = ‐0.82, p < 0.001). A main effect of PET result was observed for AD test‐related distress (β = 12.09, p < 0.001).DISCUSSION: Cognitively unimpaired adults learning elevated‐amyloid PET results reported mildly intrusive thoughts/avoidance initially following disclosure, but these symptoms decreased over time. Concern about AD dementia and AD biomarker test‐related distress remained higher in elevated‐amyloid compared to non‐elevated‐amyloid participants.Highlights: Longitudinal assessment of psychosocial reactions after amyloid PET disclosure was conducted. Transient highly intrusive thoughts or avoidance after learning elevated amyloid results. Persistent test result‐related distress after receiving elevated‐amyloid results. There is increased concern about AD dementia after receiving elevated‐amyloid results. Happiness and relief are experienced after receiving non‐elevated‐amyloid results.
- 11 August 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (9) , 6579-6589
Open AccessPsychosocial implications of learning amyloid PET results in an observational cohort
INTRODUCTION: Information on the psychosocial impact of Alzheimer's disease (AD) biomarker testing in adults at risk of AD is needed to inform best practices for communicating biomarker results.METHODS: Ninety‐nine cognitively unimpaired older adults learned amyloid positron emission tomography (PET) results (mean age = 72.0 ± 4.8, 95% White, 28% elevated amyloid). Linear mixed‐effects regression models were used to test the main effects and interaction of PET result × time on psychosocial outcomes up to 6 months after learning results.RESULTS: A significant interaction of PET result × time was observed for concern about AD (β = 0.28, p = 0.02) and intrusive thoughts and avoidance (β = ‐0.82, p < 0.001). A main effect of PET result was observed for AD test‐related distress (β = 12.09, p < 0.001).DISCUSSION: Cognitively unimpaired adults learning elevated‐amyloid PET results reported mildly intrusive thoughts/avoidance initially following disclosure, but these symptoms decreased over time. Concern about AD dementia and AD biomarker test‐related distress remained higher in elevated‐amyloid compared to non‐elevated‐amyloid participants.Highlights: Longitudinal assessment of psychosocial reactions after amyloid PET disclosure was conducted. Transient highly intrusive thoughts or avoidance after learning elevated amyloid results. Persistent test result‐related distress after receiving elevated‐amyloid results. There is increased concern about AD dementia after receiving elevated‐amyloid results. Happiness and relief are experienced after receiving non‐elevated‐amyloid results.
- Open Access
- 1 April 2024
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 10 (2) , e12483
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes
Introduction: Recruitment and retention pose a significant challenge to Alzheimer's disease (AD) research. Returning AD biomarker results to participants has been proposed as a means to improve recruitment and retention. We present findings related to participant satisfaction, utility, and impact on research attitudes from the amyloid positron emission tomography (PET) disclosure sub‐study within the Wisconsin Registry for Alzheimer's Prevention (WRAP). Methods: Ninety‐nine cognitively unimpaired WRAP participants learned their amyloid PET results (mean age ± SD = 72.0 ± 4.8). Measures of reasons for wanting to learn results, study comprehension, result utility, visit satisfaction, research attitudes, and future study enrollment willingness were collected. Between‐group, chi‐squared analysis was conducted to determine differences by result type (elevated vs. not elevated amyloid PET result) in study comprehension, result utility, and visit satisfaction. Linear mixed‐effects modeling was used to evaluate changes in research attitudes and enrollment willingness as a function of time, amyloid result type (elevated/not elevated), and their interaction. Results: The reasons most frequently endorsed for wanting to learn amyloid PET result was a “desire to contribute to research on Alzheimer's disease dementia” and “to inform preventative measures [one] might take (e.g., change diet, exercise, or other lifestyle changes).” Overall, participants reported understanding the results and found learning them useful. Satisfaction with the study visits was overwhelmingly high, with over 80% agreeing with visit usefulness and their satisfaction. Few differences were found between participants who learned an elevated and not elevated result. Over the course of the study, participants who learned an elevated amyloid PET result reported higher willingness to enroll in drug trials (beta: 0.12, p = 0.01) and lifestyle interventions (beta: 0.10, p = 0.02) compared to participants who learned a not elevated result. Discussion: Formal incorporation of disclosure practices may encourage participant recruitment and retention within AD research. Highlights: Participants wanted to learn their amyloid results to contribute to research. Satisfaction with disclosure and post‐disclosure visits was high overall. Returning AD biomarkers can increase willingness to participate in research.
- 1 April 2024
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 10 (2) , e12483
Open AccessCommunicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes
Introduction: Recruitment and retention pose a significant challenge to Alzheimer's disease (AD) research. Returning AD biomarker results to participants has been proposed as a means to improve recruitment and retention. We present findings related to participant satisfaction, utility, and impact on research attitudes from the amyloid positron emission tomography (PET) disclosure sub‐study within the Wisconsin Registry for Alzheimer's Prevention (WRAP). Methods: Ninety‐nine cognitively unimpaired WRAP participants learned their amyloid PET results (mean age ± SD = 72.0 ± 4.8). Measures of reasons for wanting to learn results, study comprehension, result utility, visit satisfaction, research attitudes, and future study enrollment willingness were collected. Between‐group, chi‐squared analysis was conducted to determine differences by result type (elevated vs. not elevated amyloid PET result) in study comprehension, result utility, and visit satisfaction. Linear mixed‐effects modeling was used to evaluate changes in research attitudes and enrollment willingness as a function of time, amyloid result type (elevated/not elevated), and their interaction. Results: The reasons most frequently endorsed for wanting to learn amyloid PET result was a “desire to contribute to research on Alzheimer's disease dementia” and “to inform preventative measures [one] might take (e.g., change diet, exercise, or other lifestyle changes).” Overall, participants reported understanding the results and found learning them useful. Satisfaction with the study visits was overwhelmingly high, with over 80% agreeing with visit usefulness and their satisfaction. Few differences were found between participants who learned an elevated and not elevated result. Over the course of the study, participants who learned an elevated amyloid PET result reported higher willingness to enroll in drug trials (beta: 0.12, p = 0.01) and lifestyle interventions (beta: 0.10, p = 0.02) compared to participants who learned a not elevated result. Discussion: Formal incorporation of disclosure practices may encourage participant recruitment and retention within AD research. Highlights: Participants wanted to learn their amyloid results to contribute to research. Satisfaction with disclosure and post‐disclosure visits was high overall. Returning AD biomarkers can increase willingness to participate in research.
- Open Access
- 1 November 2023
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 29 (s1) , 492-493
90 Feasibility of Repeated Remote Memory Assessment with Mobile Devices to Detect Subtle Cognitive Decline in Older Adults
Objective: Frequent and remote cognitive assessment may improve sensitivity to subtle cognitive decline associated with preclinical Alzheimer’s disease (AD). The objective of this study was to evaluate the feasibility and acceptability of repeated remote memory assessment in late middle-aged and older adults.Participants and Methods: We recruited participants from a longitudinal aging cohort to complete three medial temporal lobe-based memory paradigms (Object-In-Room Recall [ORR], Mnemonic Discrimination for Objects and Scenes [MDT-OS], Complex Scene Recognition [CSR]) using the neotiv application at repeated intervals over one year. We conducted initial telephone calls to perform screening, consent, and download instructions. Participants were assigned 24 remote sessions on a smartphone or tablet and were alerted via push notification when an assignment was ready to complete. Participants were randomly assigned to: (1) complete memory tests every other week or (2) complete memory tests for multiple days within one week every other month. Each remote session lasts approximately 10 minutes and includes one memory paradigm and brief usability/acceptability questionnaires followed by a delayed retrieval session 90 minutes later. Feasibility metrics examined included participation, retention, compliance, and usability/acceptability.Results: Of 150 participants recruited, 113 consented and were enrolled into the study (participation rate = 75%). Current retention rate is 75%, with 85/113 currently active (n=73) or completed (n=12). Of the 85 active or completed participants, the mean age is 68.7 (range = 4882), 64% are women, 70% used a smartphone (30% tablet), 84 are cognitively unimpaired and 1 has mild cognitive impairment. The primary threat to retention was participants consenting into the study but never registering in the app or completing their first scheduled assignment. After enrollment, 130 telephone calls were made by study staff to facilitate registration into the app or to remind participants to complete tasks. 74-80% of participants completed delayed retrieval tasks within 30 minutes of push notification, but average retrieval time was 125137 minutes post-learning trials. Regarding acceptability/usability, 94% agreed the application was easy to use, 56% enjoyed completing the mobile memory tests (36% felt neutral), 40% prefer remote mobile memory tests to standard in-person paper and pencil tests, and 50% understood the test instructions. 87% felt the frequency of tests assigned was “just right” (13% “too often”) and 90% felt the test length was “just right” (7% too short, 3% too long). Participants who completed all 24 sessions to date (n=12) all endorsed being “satisfied” or “very satisfied” with the platform and visit schedule, as well as recommended continued use of this type of cognitive testing.Conclusions: Remote memory assessment using smartphones and tablets is feasible and acceptable for cognitively unimpaired late middle-aged and older adults. Follow-up by study staff was needed to ensure adequate retention. Comprehension of instructions and compliance with completing delayed retrieval tasks within the expected timeframe was lower than expected. These feedback will be incorporated into an updated version of the app to improve compliance and retention. Longitudinal data collection is ongoing and results will be updated with a larger sample. Results will be compared across frequency schedule groups.
- 1 November 2023
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 29 (s1) , 492-493
Open Access90 Feasibility of Repeated Remote Memory Assessment with Mobile Devices to Detect Subtle Cognitive Decline in Older Adults
Objective: Frequent and remote cognitive assessment may improve sensitivity to subtle cognitive decline associated with preclinical Alzheimer’s disease (AD). The objective of this study was to evaluate the feasibility and acceptability of repeated remote memory assessment in late middle-aged and older adults.Participants and Methods: We recruited participants from a longitudinal aging cohort to complete three medial temporal lobe-based memory paradigms (Object-In-Room Recall [ORR], Mnemonic Discrimination for Objects and Scenes [MDT-OS], Complex Scene Recognition [CSR]) using the neotiv application at repeated intervals over one year. We conducted initial telephone calls to perform screening, consent, and download instructions. Participants were assigned 24 remote sessions on a smartphone or tablet and were alerted via push notification when an assignment was ready to complete. Participants were randomly assigned to: (1) complete memory tests every other week or (2) complete memory tests for multiple days within one week every other month. Each remote session lasts approximately 10 minutes and includes one memory paradigm and brief usability/acceptability questionnaires followed by a delayed retrieval session 90 minutes later. Feasibility metrics examined included participation, retention, compliance, and usability/acceptability.Results: Of 150 participants recruited, 113 consented and were enrolled into the study (participation rate = 75%). Current retention rate is 75%, with 85/113 currently active (n=73) or completed (n=12). Of the 85 active or completed participants, the mean age is 68.7 (range = 4882), 64% are women, 70% used a smartphone (30% tablet), 84 are cognitively unimpaired and 1 has mild cognitive impairment. The primary threat to retention was participants consenting into the study but never registering in the app or completing their first scheduled assignment. After enrollment, 130 telephone calls were made by study staff to facilitate registration into the app or to remind participants to complete tasks. 74-80% of participants completed delayed retrieval tasks within 30 minutes of push notification, but average retrieval time was 125137 minutes post-learning trials. Regarding acceptability/usability, 94% agreed the application was easy to use, 56% enjoyed completing the mobile memory tests (36% felt neutral), 40% prefer remote mobile memory tests to standard in-person paper and pencil tests, and 50% understood the test instructions. 87% felt the frequency of tests assigned was “just right” (13% “too often”) and 90% felt the test length was “just right” (7% too short, 3% too long). Participants who completed all 24 sessions to date (n=12) all endorsed being “satisfied” or “very satisfied” with the platform and visit schedule, as well as recommended continued use of this type of cognitive testing.Conclusions: Remote memory assessment using smartphones and tablets is feasible and acceptable for cognitively unimpaired late middle-aged and older adults. Follow-up by study staff was needed to ensure adequate retention. Comprehension of instructions and compliance with completing delayed retrieval tasks within the expected timeframe was lower than expected. These feedback will be incorporated into an updated version of the app to improve compliance and retention. Longitudinal data collection is ongoing and results will be updated with a larger sample. Results will be compared across frequency schedule groups.
- 12 October 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (4) , 282-289
Anticipated Psychological or Behavioral Reactions to Learning Alzheimer Biomarker Results
Background: As Alzheimer disease (AD) biomarker testing becomes more widely available, adults may opt to learn results. Considering potential reactions to learning biomarker results can guide prebiomarker and postbiomarker testing education and counseling programs. Methods: Cognitively healthy adults enrolled in observational Alzheimer research responded to a telephone survey about learning AD risk information (n=334; 44% Black or African American; mean age=64.9±7.0). Multiple linear regression models tested if contextual factors predicted anticipated psychological impact (distress, stigma, and cognitive symptoms) or behavior change (planning and risk-reduction). Secondary analyses tested for differences in relationships by racial identity. Results: Internal health locus of control, concern about AD, self-identified sex, education, family dementia history, and belief in AD modifiability predicted anticipated psychological impact. Concern about AD, age, racial identity, belief in AD modifiability, research attitudes, and exposure to brain health-related social norms predicted anticipated behavior change. For Black respondents, there were no sex differences in anticipated distress, whereas there were stronger relationships between health locus of control, brain health social norms, and education on outcomes compared with White respondents. Conclusions: Results may inform personalized and culturally tailored biomarker testing education and counseling to minimize psychological impacts and increase behavior change related to learning AD risk information.
- 12 October 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (4) , 282-289
Anticipated Psychological or Behavioral Reactions to Learning Alzheimer Biomarker Results
Background: As Alzheimer disease (AD) biomarker testing becomes more widely available, adults may opt to learn results. Considering potential reactions to learning biomarker results can guide prebiomarker and postbiomarker testing education and counseling programs. Methods: Cognitively healthy adults enrolled in observational Alzheimer research responded to a telephone survey about learning AD risk information (n=334; 44% Black or African American; mean age=64.9±7.0). Multiple linear regression models tested if contextual factors predicted anticipated psychological impact (distress, stigma, and cognitive symptoms) or behavior change (planning and risk-reduction). Secondary analyses tested for differences in relationships by racial identity. Results: Internal health locus of control, concern about AD, self-identified sex, education, family dementia history, and belief in AD modifiability predicted anticipated psychological impact. Concern about AD, age, racial identity, belief in AD modifiability, research attitudes, and exposure to brain health-related social norms predicted anticipated behavior change. For Black respondents, there were no sex differences in anticipated distress, whereas there were stronger relationships between health locus of control, brain health social norms, and education on outcomes compared with White respondents. Conclusions: Results may inform personalized and culturally tailored biomarker testing education and counseling to minimize psychological impacts and increase behavior change related to learning AD risk information.